Compare Bristol-Myers Squibb Co (BMY) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Icl Group Ltd — how do they compare? Bristol-Myers Squibb Co trades at $58.63 (market cap $116.30B), while Icl Group Ltd trades at $5.05 (market cap $6.49B). The key difference: Bristol-Myers Squibb Co is far larger — about 17.9× Icl Group Ltd's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | ICL | |
|---|---|---|
Market Cap | $116.30B | $6.49B |
Sector | Health | Basic Materials |
52-Week High | $62.37 | $7.03 |
52-Week Low | $42.60 | $4.80 |
Enterprise Value | $152.24B | $9.06B |
Dividend Yield | 4.42% | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
ICL trades at $4.93, up 1.65% today, with a bearish technical signal and neutral oscillators. The company reported Q1 2026 EPS of $0.11, beating expectations, and maintains a dividend of $0.05. Revenue for 2025 was $7.15B with a net income margin of 3.52%, while valuation ratios like P/E of 23.48 and P/S of 0.86 suggest moderate pricing. Recent news highlights a $800M senior notes offering completed in June 2026.
Outlook is mixed: earnings beats and dividend yield offer support, but declining profit margins and bearish analyst consensus (100% hold) indicate caution. Key risks include raw material costs and forex headwinds, with institutional sentiment leaning neutral amid stable cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
